Sodium‐glucose co‐transporter‐2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: A network and cumulative meta‐analysis of randomized controlled trials
- 31 March 2017
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 19 (8) , 1106-1115
Abstract
Aim: To compare the associations of individual sodium‐glucose co‐transporter ‐ 2 ( SGLT2 ) inhibitors with adverse renal outcomes in patients with type 2 diabetes mellitus ( T2DM ). Methods: PubMed , EMBASE , CENTRAL and ClinicalTrials.gov were searched for studies published up to M ay 24, 2016, without language or date restrictions. Randomized trials that reported at least 1 renal‐related adverse outcome in patients with T2DM treated with SGLT2 inhibitors were included. Pairwise and network meta‐analyses were carried out to calculate the odds ratios ( ORs ) with 95% confidence intervals ( CIs ), and a cumulative meta‐analysis was performed to assess the robustness of evidence. Results: In total, we extracted 1334 composite renal events among 39 741 patients from 58 trials, and 511 acute renal impairment/failure events among 36 716 patients from 53 trials. Dapagliflozin was significantly associated with a greater risk of composite renal events than placebo ( OR 1.64, 95% CI 1.26‐2.13). Empagliflozin seemed to confer a lower risk than placebo ( OR 0.63, 95% CI 0.54‐0.72), canagliflozin ( OR 0.48, 95% CI 0.29‐0.82) and dapagliflozin ( OR 0.38, 95% CI 0.28‐0.51). With regard to acute renal impairment/failure, only empagliflozin was significantly associated with a lower risk than placebo ( OR 0.72, 95% CI 0.60‐0.86). The cumulative meta‐analysis indicated the robustness of our significant findings. Conclusions: The present meta‐analysis indicated that dapagliflozin may increase the risk of adverse renal events, while empagliflozin may have a protective effect among patients with T2DM . Further data from large well‐conducted randomized controlled trials and a real‐world setting are warranted.Keywords
Funding Information
- Indiana University Health-Indiana University School of Medicine Strategic Research Initiative
This publication has 41 references indexed in Scilit:
- The Role of the Kidney and SGLT2 Inhibitors in Type 2 DiabetesCanadian Journal of Diabetes, 2015
- Glucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetesTherapeutic Advances in Endocrinology and Metabolism, 2015
- Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of actionJournal of Diabetes Investigation, 2014
- Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysisJournal of the American Society of Hypertension, 2014
- Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic controlKidney International, 2014
- Efficacy and safety of sodium glucose co‐transport‐2 inhibitors in type 2 diabetes: a meta‐analysis of randomized clinical trialsDiabetes, Obesity and Metabolism, 2013
- Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 DiabetesAnnals of Internal Medicine, 2013
- SGLT2 inhibition in diabetes mellitus: rationale and clinical prospectsNature Reviews Endocrinology, 2012
- Glucose Control by the Kidney: An Emerging Target in DiabetesAmerican Journal of Kidney Diseases, 2009
- Changes in blood pressure before the development of nosocomial acute kidney injuryNephrology Dialysis Transplantation, 2008